Brief: Nrx Pharmaceuticals Reports Q3 2022 Financial Results
14/11/2022 11:57
Nov 14 (Reuters) - Nrx Pharmaceuticals Inc NRXP.O :
* NRX PHARMACEUTICALS REPORTS THIRD QUARTER 2022 FINANCIAL
RESULTS
AND PROVIDES BUSINESS UPDATE
* QTRLY LOSS PER SHARE $0.14
* NRX PHARMA - PLANS TO INITIATE PHASE 3 TRIAL OF NRX-101 IN
PATIENTS WITH BIPOLAR DEPRESSION WITH ACUTE SUICIDAL IDEATION
AND BEHAVIOR BY YEAR-END
Source text for Eikon: ID:nPn5mfgPha
Further company coverage: NRXP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on NRX Pharmaceuticals
See all newsBrief: NRx Pharmaceuticals Reschedules Conference Call To Discuss Third Quarter And Year To Date 2024 Financial Results To November 18, 2024
U.S. RESEARCH ROUNDUP-Cintas Corp, Sprouts Farmers market, Voya Financial
U.S. STOCKS ON THE MOVE-Molson Coors, Starbucks, Warner Bros Discovery
U.S. STOCKS ON THE MOVE-Zebra Technologies, Ecolab, American Electric Power
NRX Pharmaceuticals Inc expected to post a loss of 7 cents a share - Earnings Preview